...
首页> 外文期刊>BMJ Open >Total glucosides of paeony for rheumatoid arthritis: a protocol for a systematic review
【24h】

Total glucosides of paeony for rheumatoid arthritis: a protocol for a systematic review

机译:类风湿关节炎白pa总苷:系统评价方案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction Total glucosides of paeony (TGP) is a natural plant extract, which is widely used in China for treating rheumatoid arthritis (RA). Many relevant randomised controlled trials (RCTs) of TGP for RA are available, but they have not been systematically reviewed. This systematic review aims to examine the effectiveness and safety of TGP in patients with RA. Methods and analyses We will search for RCTs of TGP in the treatment of RA, performed up until February 2016, in PubMed, Embase, Cochrane Central Register of Controlled Trials, and four Chinese databases (Chinese Biomedical Database, China National Knowledge Infrastructure, Wanfang Database and Chinese Scientific Journal Database). Trial registers and reference lists of retrieved articles will also be searched to identify potential articles. RCTs comparing TGP with placebo, no treatment, or disease-modifying antirheumatic drugs for patients with RA will be retrieved. The primary outcomes will be disease improvement and disease remission. The secondary outcomes will be surrogate outcomes, symptoms, adverse effects, and quality of life. Two reviewers will independently extract data on participants, interventions, comparisons, outcomes, etc. The methodological quality of each included study will be evaluated using the Cochrane risk of bias tool, and the strength of evidence on prespecified outcomes will be assessed in accordance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Review Manager 5.3 software will be used for data analyses. Meta-analyses will be performed if the data are sufficiently homogeneous, both statistically and clinically. Possible publication bias will also be checked using funnel plots once the number of included studies is sufficient. Ethics and dissemination Ethics approval is not required, as this study will not involve patients. The results of this study will be submitted to a peer-reviewed journal for publication, to inform both clinical practice and further research. Trial registration number CRD42015026345.
机译:简介牡丹总苷(TGP)是一种天然植物提取物,在中国广泛用于治疗类风湿关节炎(RA)。目前已有许多有关RA的TGP的相关随机对照试验(RCT),但尚未对其进行系统的审查。该系统评价旨在检查TGP在RA患者中的有效性和安全性。方法和分析我们将在PubMed,Embase,Cochrane对照试验中心注册以及四个中文数据库(中国生物医学数据库,中国国家知识基础设施,万方数据库)中搜索截至2016年2月进行的TGP治疗RA的RCT。和中国科技期刊数据库)。还将检索检索到的文章的试验登记册和参考清单,以识别潜在的文章。将检索将TGP与安慰剂,未治疗或可缓解疾病的抗风湿药用于RA患者的RCT。主要结果将是疾病改善和疾病缓解。次要结果将是替代结果,症状,不良反应和生活质量。两名审稿人将独立提取参与者,干预措施,比较,结果等方面的数据。将使用Cochrane偏倚风险工具评估每项纳入研究的方法学质量,并根据评估结果评估预先指定结果的证据强度。 GRADE(建议书分级评估,制定和评估)方法。 Review Manager 5.3软件将用于数据分析。如果数据在统计和临床上都足够均匀,将进行荟萃分析。一旦纳入研究的数量足够,还将使用漏斗图检查可能的发表偏倚。伦理学和传播不需要伦理学批准,因为该研究不会涉及患者。这项研究的结果将提交给同行评审期刊发表,以告知临床实践和进一步的研究。试用注册号CRD42015026345。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号